Novel PA-9 analog, acting as an antagonist of the PAC1 receptor, showing improved antagonistic activities than PA-9

Prodrug of antitumor agent oncrasin-72, with improved stability, pharmacokinetics, and safety

Novel potent and highly selective KDM1A chemoprobe, exhibiting a selectivity profile similar to the parent compound ORY-1001

PET Precursor of VU0467485

Negative control for NVS-MLLT-1

Nagative control for NVS-BPTF-1

Prodrug of NUC013, a novel DNA methytransferase inhibitor

Negative control for Homer

The negative control compound for ML323

Novel Highly Selective Inhibitor of Methyltransferase DOT1L, being more metabolically stable and significantly less toxic in vivo than pinometostat

Novel potent antitubercular agent, inhibiting decaprenylphosphoryl-β-d-ribose 2'-oxidase (DprE1), displaying better aqueous solubility and metabolic stability than PBTZ169

Negative control for MDC-4381

Negative control for MS4322

Negative control for MS154

Prodrug of MRS4738, dramatically reducing lung inflammation in a mouse asthma model

Negative control for MRK-740

Negative control for MLi-2

Negative control for MF-094

TH10785 is a small-molecule activator that binds to the active site of 8-oxo guanine DNA glycosylase 1 (OGG1) and enables the protein to completely cleave the damaged DNA strand, which results in an overall increased repair of oxidative DNA damage.

NCDM-32B is a novel potent and selective KDM4 inhibitor, impairing viability and transforming phenotypes of basal breast cancer.

Tryptolinamide (TLAM) is a small-molecule compound that activates mitochondrial respiration in cybrids generated from patient-derived mitochondria and fibroblasts from patient-derived iPSCs, inhibits phosphofructokinase-1 (PFK1) with an ATP-uncompetitive

VX-984 (M 9831) is a potent, selective inhibitor of DNA-PK with IC50 of 88±64 nM for inhibition of DNA-PKcs autophosphorylation (Ser2056) in A549 lung cancer cells, with good selectivity versus other PI3K family members..

AZD5305 is a potent, selective and oral active PARP inhibitor. AZD5305 is a highly potent inhibitor of PARP1, with significant PARP1-DNA trapping activity, no PARP2-activity, nor binding activity to any other members of the PARP family. AZD5305 has excellent secondary pharmacology and physicochemical properties as well as high oral bioavailability in preclinical species.

γ-AA peptide P6 (Cyclic γ-AA P6) is a potent activator of E6 associated protein (E6AP). γ-AA peptide P6 can stimulate the self-ubiquitination of E6AP and E6AP-catalyzed substrate ubiquitination in reconstituted reactions in vitro. γ-AA peptide P6 can also enhance the ubiquitination of E6AP substrates in the cell and accelerate their degradation by the proteasome.

MCC7840 sodium, a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC50 of <100 nM. MCC7840 sodium can be used for the research of inflammatory diseases.

YM-344031 is a potent, selective, brain-penetrable CCR3 antagonist with binding IC50 of 3.0 nM, inhibits ligand-induced Ca(2+) flux with IC50 of 5.4 nM.

cyclo-CRVLIR is a cyclic peptide that binds selectively to p110α RAS binding domain (p110α-RBD) with ITC Kd of 3 uM, blocks p110α/RAS interaction in vitro and KRAS cancer cell lines.

Novel RBP4 antagonist with good in vitro potency and selectivity and optimal rodent pharmacokinetic (PK) and pharmacodynamic (PD) characteristics

IK930 (compound I-32) is a potent and orally active TEAD inhibitor with an EC50 value of <0.1 µM.